They also demonstrated that inhibitors of MDR1 pump (i.e., tariquidar) or the use of RTKs inhibitor lapatinib restored sensitivity of PROTAC-resistant cancer cells to protein degraders [89]. Here, ABCB1 is linked to cancer.